Dr. Schmoll on the Toxicity of the CHARTA Study in CRC

Hans-Joachim Schmoll, MD
Published: Tuesday, Oct 10, 2017



Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.

Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
 
SELECTED
LANGUAGE


Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.

Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x